Thus, arguing that free IL15 alone is not only sufficient in anti-tumor therapies, but could potentially be better tolerated as a therapeutic by predominantly targeting NK cells and avoiding overwhelming CD8+ T cell activity. This evidence concerns the gene CD8A and neoplasm.